SCHEMBL370189

SCHEMBL370189

NC(=O)NS(=O)(=O)c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.56
MMP2 P08253 2/20 0.56
CA1 P00915 2/20 0.56
MMP1 P03956 1/20 0.56
MMP9 P14780 1/20 0.56
MMP8 P22894 1/20 0.56
MMP13 P45452 1/20 0.56
PTGS2 P35354 4/20 0.55
PTGS1 P23219 2/20 0.55
KDM4E B2RXH2 2/20 0.55
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
LMNA P02545 1/20 0.53
HPGD P15428 1/20 0.53
GAA P10253 1/20 0.51
LARS1 Q9P2J5 1/20 0.51
MMP14 P50281 1/20 0.50
BCAT1 P54687 1/20 0.50
CA9 Q16790 1/20 0.49
EGFR P00533 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5605338 0.98 CA2 (0.54) CA2MMP2CA1MMP1MMP9
SCHEMBL29176138 0.92 HTR6 (0.52) CA2MMP2CA1MMP1MMP9
Ether SCHEMBL11029157 0.86 KDM4E (0.50) CA2MMP2PTGS2PTGS1KDM4E
SCHEMBL3928655 0.83 CA2 (0.52) CA2MMP2CA1MMP1MMP9
SCHEMBL6012074 0.82 CA2 (0.60) CA2MMP2CA1MMP1MMP9
SCHEMBL10931933 0.82 CA2 (0.60) CA2MMP2CA1MMP1MMP9
SCHEMBL453442 0.82 CA2 (0.60) CA2MMP2CA1MMP1MMP9
Sulfacarbamide SCHEMBL8024629 0.81 KMT2A (0.69) CA2MMP2CA1MMP1MMP9
SCHEMBL29030151 0.81 BCAT1 (0.43) CA2MMP2CA1MMP1MMP9
SCHEMBL1269819 0.81 CA2 (0.54) CA2MMP2CA1MMP1MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1087 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120059262-A Material for thermal printing wrist strap and preparation method thereof 中裕(惠州)科技有限公司 2025-05-30 CN claimed
CN-116813522-A Preparation method and application of indole-containing benzenesulfonyl urea compound 广州方中化工有限公司 2023-09-29 CN claimed
US-20230301946-A1 THROMBOXANE RECEPTOR ANTAGONIST FORMULATIONS ATXA THERAPEUTICS LIMITED (IE) 2023-09-28 US claimed
CN-116601149-A Aminoquinazoline derivatives as P2X3 inhibitors 奇斯药制品公司 2023-08-15 CN claimed
CN-116234539-A Thrombus receptor antagonist formulations ATXA治疗有限公司 2023-06-06 CN claimed
EP-4178547-A1 THROMBOXANE RECEPTOR ANTAGONIST FORMULATIONS ATXA Therapeutics Limited (IE) 2023-05-17 EP claimed
CN-112210164-B Polyolefin material and preparation method thereof 金发科技股份有限公司 2023-03-21 CN claimed
US-20220233501-A1 THERAPEUTIC COMBINATIONS SUPERSALUS INC (US) 2022-07-28 US claimed
CN-114766485-A Application of semi-rigid acylhydrazone ligand in herbicide and composite herbicide based on semi-rigid acylhydrazone ligand 兰州大学 2022-07-22 CN claimed
WO-2022008515-A1 THROMBOXANE RECEPTOR ANTAGONIST FORMULATIONS ATXA THERAPEUTICS LIMITED (IE) 2022-01-13 WO claimed
EP-0006587-B1 SULFONYL UREAS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM HOECHST AKTIENGESELLSCHAFT (DE) 1981-11-11 EP claimed
US-4157395-A TREATMENT OF DIABETES HOECHST AKTIENGESELLSCHAFT (DE) 1979-06-05 US claimed
US-4132795-A Benzenesulfonyl ureas and their use for the treatment of diabetes mellitus HOECHST AKTIENGESELLSCHAFT (DE) 1979-01-02 US claimed
US-4029666-A Benzenesulfonyl-ureas and process for preparing them HOECHST AKTIENGESELLSCHAFT (DT) 1977-06-14 US claimed
US-4025519-A HYPOGLYCEMIC AGENTS HOECHST AKTIENGESELLSCHAFT (DT) 1977-05-24 US claimed
US-3998968-A Benzenesulfonyl ureas and process for their manufacture HOECHST AKTIENGESELLSCHAFT (DT) 1976-12-21 US claimed
US-3962244-A LOWERING OF BLOOD-SUGAR LEVELS HOECHST AKTIENGESELLSCHAFT (DT) 1976-06-08 US claimed
US-3961067-A Composition comprising a benzenesulfonylurea hypoglycemic agent and method of treatment PFIZER INC. (US) 1976-06-01 US claimed
US-3961065-A HYPOGLYCEMIC AGENTS PFIZER INC. (US) 1976-06-01 US claimed
US-3942973-A Herbicidal compositions containing para-substituted benzenesulfonylureas and salts thereof and methods of employing such compositions THE O. M. SCOTT & SONS COMPANY (US) 1976-03-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230301946-A1 THROMBOXANE RECEPTOR ANTAGONIST FORMULATIONS TBXA2R, TBXAS1, UTS2R CA2 3791/4885MMP2 2296/4885CA1 4642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.